Journal
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
Volume 44, Issue 5, Pages 928-933Publisher
WILEY
DOI: 10.1111/ijlh.13931
Keywords
ASXL1; fragment analysis; marker; myeloid neoplasms; prognosis
Categories
Funding
- Molecular biology team, Haematology Cochin Hospital
Ask authors/readers for more resources
This study developed a fragment analysis method (PCR-Fluo-ASXL1-FA) that can rapidly, accurately, and cost-effectively detect mutations in the ASXL1 gene. Compared to other methods, this approach can detect insertional mutations in the ASXL1 region and has high sensitivity. Through three practical cases, the feasibility of this technique has been demonstrated.
Introduction The additional sex combs like 1 (ASXL1) gene is frequently mutated in a number of haematological neoplasms. The c.1934dupG, known to be the most common alteration in ASXL1, is associated with poor clinical outcome. A systematic determination of ASXL1 mutational status in myeloid malignancies is therefore necessary for prognostic stratification. Methods Because direct sequencing is not sensitive and next-generation sequencing (NGS) is time-consuming, expensive and sometimes does not allow the detection of the c.1934dupG, we have developed a fragment analysis assay, complementary to NGS, that allows the detection of c.1934dupG mutation in addition to other nearby insertions/deletions of ASXL1 located close to it. We called this assay the PCR-Fluo-ASXL1-FA. Results First, we evaluated the efficiency of our approach compared to NGS and Sanger. We showed that PCR-Fluo-ASXL1-FA could detect all insertional mutations of ASXL1 located on its area, with a high sensitivity (1.5%). Then, we have illustrated the interest of this technique by three concrete cases. Discussion In summary, we have established a fragment analysis approach, which can detect most ASXL1 mutations, in particular the c.1934dupG, in a sensitive, fast and inexpensive manner. We therefore recommend the synchronous use of this method with NGS, to ensure complete detection of all clinically relevant ASXL1 mutations in patients suffering with myeloid neoplasms.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available